Minority Stake Aims to Expand Global Reach
Estée Lauder Companies Inc. announced a strategic minority investment in 111SKIN, the luxury clinical skincare brand founded by Dr. Yannis Alexandrides. While the terms of this investment remain undisclosed, it aims to expand Estée Lauder’s luxury skincare portfolio significantly.
Founded in 2012, 111SKIN was created to help patients recover faster after surgical procedures. Its pioneering NAC Y2™ technology plays a central role in supporting skin repair and maintaining a radiant complexion. The product range now includes more than 30 items, with prices ranging from $50 to $1,000.
“Skin care is entering a new phase, shaped by the convergence of procedures, longevity, and beauty,” explained Stéphane de La Faverie, President and CEO of The Estée Lauder Companies. Consumers increasingly seek products delivering visible, treatment-inspired results, and 111SKIN exemplifies this shift by translating Dr. Alexandrides’ 35 years of surgical experience into high-performance luxury skincare.
Dr. Alexandrides’ clinical expertise has led to a diversified product portfolio anchored by its Black Diamond and Reparative collections. These collections reflect the brand’s commitment to cutting-edge skincare solutions.
Global Distribution and Market Reach
Through a robust global distribution network, 111SKIN products are available via luxury retail, e-commerce, and high-end spa channels like Harrods, Nordstrom, and Mandarin Oriental. The brand also maintains a strong direct-to-consumer business, representing about 20% of total sales, which indicates strong digital engagement with prestige consumers.
Expected to account for approximately 40% of 2025 sales, North America plays a significant role in the brand’s global presence. 111SKIN has also established itself in China, the United Kingdom, Europe, and Asia Pacific, marking its status as a major player in the luxury skincare sector.
Expressing excitement about their partnership with The Estée Lauder Companies, Dr. Yannis and Eva Alexandrides, co-founders of 111SKIN, look forward to building on momentum and driving future growth. CEO Vanessa Goddevrind highlighted plans to leverage this investment to facilitate expansion while preserving the brand’s distinctive approach.
This investment aligns with Estée Lauder’s focus on science-driven innovation and enhancing their portfolio with advanced skincare solutions. The partnership is expected to meet the increasing consumer demand for high-performance and preventative care products.
